AAV manufacturing for clinical and commercial gene therapies
In this webinar, Thermo Fisher Scientific describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.
Accelerating Advancement in Gene Therapy by Improving Downstream Purification of Viral Vectors
In this webinar, you'll learn more about the performance characteristics of a true pan-tropic AAV resin—POROS CaptureSelect AAVX
Development and Validation of Quantitative Real-Time PCR for the Detection of Residual HEK-293 Host Cell DNA
In this webinar, we share the development and validation of a new, and highly sensitive and accurate solution for detecting and quantifying residual HEK293 host cell DNA to help meet regulatory requirements.
Innovations in viral vector development, scale up and production
Watch this educational webinar and learn how recent innovation can help you to significantly push the boundaries of viral vectors productivity and quality.
HyPerforma Single-Use Fermentor Overview
Learn about the unique features and advantages of our HyPerforma Single-Use Fermentor, the first single-use system specifically engineered for microbial fermentation.
Affinity chromatography accelerates viral vector purification for gene therapies
A case study demonstrates that affinity chromatography can offer efficiency and scalability for gene therapy manufacturing using viral vectors.
Development of purification steps for several AAV serotypes using POROS CaptureSelect AAVX affinity chromatography
Learn more about Capture Select technology minimizing the steps in the purification process.
End-user evaluation of 30 L and 300 L HyPerforma S.U.F.s and scale-down model
In moving processes from bench to pilot and ultimately production fermentors, it is critical to have a reliable scaledown model.
Production of therapeutic plasmid DNA in single-use fermentors
The manufacturing of plasmid DNA is becoming a supply bottleneck due to rapidly growing demand for various gene-targeting biotherapeutics.
Upstream and downstream solutions for AAV manufacturing
With the advancement of gene delivery vectors and gene editing technologies, cell and gene therapies are a very real solution to many previously untreatable or difficult to treat diseases